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Abstract
Background: Abacavir (ABC) may be associated with a small, increased risk of myocardial infarction in HIV-infected adults,
possibly related to cytokine-mediated inflammation.
Methods: To evaluate the induction of inflammatory cytokine transcription by ABC, we used samples from women randomized
to receive zidovudine/lamivudine/ABC (Trizivir) or lopinavir/ritonavir and zidovudine/lamividine (Kaletra/Combivir) from the
third trimester through six-months postpartum for the prevention of mother-to-child transmission (PMTCT). Women were
matched by CD4 count and baseline HIV RNA. All women attained viral suppression (B50 copies/ml) by the time of sampling.
Results: Four cytokines showed a difference in expression between the treatment arms, all in a proinflammatory direction
for the ABC arm: CD40LG 1.82-fold, (p.027); IL-8 3.16-fold (p.020); LTA 2.82-fold, (p.008); and CCL5 1.67-fold,
(p.035). At 12-months postpartum, 6-months after antiretroviral discontinuation, cytokine expression was similar by
treatment arm.
Conclusions: We conclude that ABC may upregulate proinflammatory cytokines at the transcriptional level in this population.
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Introduction
Abacavir (ABC) may be associated with a small, increased risk
of myocardial infarction (MI) in HIV-infected adults, possibly
related to cytokine-mediated inflammation; however, no
consistent outcome has been found in studies reporting
cytokine levels during ABC treatment.
Data for increased cardiovascular disease (CVD) with ABC
use are mixed. The D:A:D study, with over 178,000 person-
years of follow-up, reported that recent ABC use was
associated with a 68% increased risk of MI [1]. In the SMART
study, sub-group analysis showed that ABC, compared with
other NRTIs, was associated with increased risk of MI, major
cardiac event (MI, stroke and cardiovascular surgery) and an
expanded CVD risk definition (including MI, stroke, heart
failure and sudden death), although the use of ABC was not
randomized [2]. In a nested case-control study from France,
increased risk of MI was found in patients exposed to ABC
for less than one year or with recent use, but not in others
(OR, 2.01, 95% CI, 1.11 to 3.64) [3].
Other studies dispute these apparent associations. Glax-
oSmithKline (GSK) published their cumulative analysis from
54 GSK-sponsored clinical studies and found no increased risk
of MI with ABC use; overall incidence of MI was low and
equal in both groups [4]. In ACTG A5001 (ALLRT), using data
from 5056 treatment-naı ¨ve patients randomized in multiple
clinical trials, there was no evidence that ABC was associated
with either short- or long-term increased MI or CVD risk in
patients randomized to ABC as their initial regimen [5]. Two
meta-analyses recently conducted both suggest that there is
no link between ABC use and CVD [6,7].
The mechanism for the increased cardiovascular risk
suggested in some studies is unclear. It has been proposed
that the risk may be independent of traditional cardiovas-
cular risk factors since it has been largely confined to the
period of actual ABC exposure [1]. Several studies have
looked at putative mechanisms for the increased cardiovas-
cular risk and suggest that increased platelet reactivity and
enhanced leukocyte/endothelial cell interactions may be
responsible [810]. The SMART study detected higher levels
of the proinflammatory markers hsCRP and IL-6 in those
receiving ABC compared with other NRTIs. However, whether
changes in circulating inflammatory biomarkers associated
This work was previously presented as a poster presentation, abstract 816, at
the 18th Conference on Retroviruses and Opportunistic Infections, Boston,
February 2011.
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1with CVD occur during treatment with ABC has yet to be
conclusively resolved [1113].
In this study, we evaluated samples at two timepoints from
a cohort of women who were randomized to either ABC-
based or PI (protease inhibitor)-based antiretrovirals as part
of a prevention of mother-to-child transmission (PMTCT)
regimen. We measured transcription levels of selected
inflammatory markers immediately following six to eight
months of treatment and again at six months post-exposure
to determine if these cytokines were differentially regulated
in patients during and after treatment with ABC compared to
those on a PI-based regimen.
Materials and methods
Study population
Samples were obtained from patients enrolled in the Mma
Bana Study, a randomized, placebo-controlled clinical trial
conducted by the BotswanaHarvard AIDS Institute (BHP) to
determine the optimal antiretroviral therapy (ART) regimen
to reduce vertical transmission in breastfeeding women [14].
This study enrolled 560 HIV-positive, treatment naı ¨ve, preg-
nant women randomized to either ABCzidovudine
lamivudine (Arm A) vs. lopinavir/ritonavirzidovudine
lamivudine (Arm B) from 26 to 34-weeks gestation to
six months postpartum. Stored samples were available at
6-months postpartum (on treatment) and 12-months postpar-
tum (off treatment). Study drugs were provided as previously
reported [14]. The Health Research Development Committee
of Botswana and the Human Subjects Committee of the
Harvard School of Public Health approved the study protocol
andamendments.Anindependentdataandsafetymonitoring
board reviewed safety and efficacy data approximately every
six months. Participants were provided with study consent
informationinEnglishand/orthelocalSetswanalanguageand
agreed to the use of stored samples for future research
projects.The full study protocol is available as an appendix to
the original parent study [14].
Subjects were chosen for this sub-study by allocating a
random number (Microsoft Excel, RAND() function) to each
patient ID in the ABC -based arm, ranking the associated
number in ascending order and selecting the first 40 patients.
Subjects from the PI-based arm were chosen by matching for
CD4 and viral load. Clinical characteristics of the participants
are provided in Table 1.
RNA purification
Plasma and buffy coat were separated by density gradient
centrifugation shortly after collection. Buffy coat fractions
were stored at 808C and went through a single freeze
thaw cycle immediately prior to cellular RNA purification.
Total RNA from buffy coat was extracted using a hybrid Trizol
and Qiagen RNeasy mini kit protocol (Qiagen, Valencia, CA,
USA); 250 ml of buffy coat was added to 1 ml Trizol BD
(Sigma, St. Louis, MO, USA), vortexed briefly and incubated at
room temperature for 15 minutes; 135 ml of 1-bromo-
3-cholopropane was added and then vortexed before
another 15-minute incubation. The crude lysate was centri-
fuged at 12,000g for 15 minutes in order to separate the
phases. Afterwards, 500 ml of the aqueous phase was
removed and added to 500 ml 75% ethanol. The sample
was then passed through an RNeasy spin following the
manufacturer’s protocol. Only RNA with an A260:A230 ratio
 1.7, an A260:A280 ratio  1.8 and a concentration  40
ng/ml was considered of sufficiently high quality for use in
real-time PCR.
RT
2 Profiler assay
Gene expression was quantified using an RT
2 Profiler
inflammatory response and autoimmunity PCR array accord-
ing to the manufacturer’s instructions (SABiosciences, Fre-
derick, MD, USA). The cycle time (Cq) values from these
reactions were interpreted by using SABiosciences’ PCR array
data analysis tool to calculate the DDCq and the fold change
[fold change2
(DDCq)]. The RT
2 Profiler assay also verified
the absence of genomic DNA and inhibitors of reverse
transcription and real-time PCR to ensure consistency
between samples.
Real-time PCR validation of results
cDNA synthesis was carried out with the Transcriptor High
Fidelity kit (Roche, Randburg, South Africa) according to the
manufacturer’s protocol using oligo dT as the priming
method and a extension temperature of 558C. Real-time
PCR was performed on cDNA using the DyNAmo HS SYBR
Green qPCR kit (New England Biolabs, Ipswich, MA, USA).
Primers were designed using Primer-BLAST (Table S1 in
Additional file 1). Data were acquired in an ABI 7500 under
the following cycling conditions: 958C for 15 minutes
followed by 45 cycles of 948C for 10 seconds, annealing at
658Co r6 7 8C for 30 seconds and extension at 728C for 32
seconds during which time the fluorescence was acquired.
The optimal annealing temperature was determined empiri-
cally. Baseline fluorescence and cycle threshold were calcu-
lated automatically by the SDS software v1.4.
Data analysis
In-house qPCR assays for each patient were done in triplicate
to determine mRNA transcripts levels for each cytokine.
The median mRNA quantity for a cytokine in each arm was
determined by transforming the Cq values using 2
(DCq), after
correction for primer efficiency using the Pfaffl method, and
compared to give a fold-change in expression [15]. A p-value
was calculated by Student’s t-test after correction for outliers
using Grubbs’ test with an alpha of 0.05 for all statistical
tests. Correction for multiple comparisons was carried out
using the BenjaminiHochberg method to control the false
discovery rate [16].
Results
The preliminary cytokine analysis involved 10 individuals
from each arm that were matched for CD4 count and viral
load at baseline and were confirmed to have full virologic
suppression (B50 RNA copies/ml) at six months postpartum
(time of ART cessation). Cellular gene expression was
quantified by RT
2 PCR Array and the average DCq value
was calculated for each gene in both treatment arms.
The majority of cytokines on the PCR array were considered
to have insufficient expression for analysis, which was
defined as a Cq value  35 (Table S2 in Additional file 1).
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2Eight out of 86 genes demonstrated a greater than 50%
change in gene expression in those treated with ABC-based
vs. PI-based antiretrovirals (Table S2 in Additional file 1).
These genes were chosen for expanded analysis: ccl2, ccl5,
ccr7, cd40, cxcl1, cxcl5, il8 and lta. To account for false
negatives, nfkb1, tollip, ifng and cd40lg were included in the
subsequent qRT-PCR despite showing B50% change in
expression between arms in the preliminary analysis.
For the main analysis, 30 new individuals from each arm
were similarly matched for CD4 count and viral load. Cellular
RNA was purified from stored buffy coat taken at six months
postpartum and from 24 patient-matched samples available
at 12-months postpartum. Cellular gene expression was
quantified by real-time PCR and the median DCT value was
calculated for each gene of the 12 genes in both treatment
arms (Figure 1).
At six-months postpartum, those treated with an ABC-
containing regimen showed significantly higher transcription
of CD40 ligand (CD40LG), IL-8 and lymphotoxin alpha (LTA)
and significantly lower CCL5 (RANTES) levels (Figure 1,
Table 2a). The respective p-values were adjusted for multiple
testing by the BenjaminiHochberg approach. All observed
changes in transcription were in a proinflammatory direction
for ABC: CD40LG, 1.82 (90.35) fold (p.027); IL-8, 3.16
(90.87) fold (p.020); LTA, 2.82 (90.65) fold (p.008);
and CCL5, 1.67 (90.33) fold (p.035). There was a non-
significant trend for an increase in TOLLIP expression in the
ABC-treated group (2.34 (90.86) fold, p.14). By 12-
months postpartum, when both arms had received no ART
for 6-months, there was no difference in transcription of
the five cytokines between the treatment arms (Figure 2,
Table 2a).
At the six-month study visit when ART was discontinued,
all participants were virologically suppressed, and by 12-
months postpartum, all individuals had an expected rebound
plasma viraemia. Within each arm, there was a significant
increase at 12-months postpartum compared to 6-months
in CCL5, CXCL1, CD40LG and IL-8 in both arms (Figure 2). At
12 months, LTA had significantly decreased transcription
(3.64 (91.03) fold; p.001) in women treated with
Trizivir compared with levels detected at six-months. In
women treated with Kaletra/Combivir, there was no change
in transcription between timepoints (1.03 (90.27) fold;
p.90) (Figure 3, Table 2b).
Figure 1 highlights the presence of outliers in each
treatment arm that is greater than three standard devia-
tions from the mean and were confirmed by Grubbs’ test
(pB.05). Removing these single outliers resulted in a true
Gaussian distribution. A more conservative approach is to
utilize a MannWhitney test, rather than a Student’s t-test,
to compare cytokine expression in the two treatment arms
at 6 and 12 months, which reduces the influence of out-
lying values. A MannWhitney test would give a p.41
for the differences in LTA transcription between the two
treatment arms at six months, as compared to p.08
that we determined using an established correction method.
Exclusion of the outliers does not alter the final signifi-
cance of the results at pB.05 (Table S3 in Additional
file 1).
Discussion
This is the first report of differences in cytokine expression
mediated at the transcriptional level in HIV-infected indivi-
duals treated with an ABC-containing regimen. Previous
studies chose to assess circulating inflammatory mediators
based on their reported associations with CVDs and systemic
inflammation. Our approach allowed us to simultaneously
profile the expression of a large number of cytokines in two
treatment groups, and these results suggest a heightened
transcriptional response for inflammatory mediators in those
treated with ABC.
One of the four cytokines that showed a significant change
in expression, CD40LG, has also been shown to be elevated in
the plasma of an ABC-treated animal model [17]. CD40 ligand
is expressed primarily on activated CD4
 T cells, platelets
and vascular smooth muscle cells and, under inflammatory
conditions, is also induced on monocytes and NK cells [18].
Ligation with CD40 leads to the production of reactive oxygen
species and adhesion molecules that promote a local
inflammatory reaction. Both of these molecules are increased
in atherosclerotic plaques and their coupling triggers athero-
genic signalling events and the upregulation of VCAM-1,
ICAM-1, various interleukins, including IL-8 and members of
the TNF superfamily such as LTA. LTA itself mediates a large
Table 1. Clinical characteristics of study participants
Arm A (zidovudine/lamivudine/
abacavir) (n30)
Arm B (zidovudine/lamivudine/lopinavir/
ritonavir) (n30)
Age at enrolment, median years (IQR) 29 (25 to 33) 25 (22 to 28)
HIV RNA levels at enrolment, median
(log10 copies/ml)
3.98 (3.65 to 4.46) 3.90 (3.50 to 4.17)
CD4
 count at enrolment, median cells/ml (IQR) 410 (347 to 579) 393 (338 to 491)
HIV RNA levels at treatment cessation, median
(log10 copies/ml)
50 50
CD4
 count at treatment cessation, median
cells/ml (IQR)
591 (468 to 729) 585 (470 to 835)
IQR, interquartile range.
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3number of inflammatory responses and could be associated
with CVD via the concomitant induction of adhesion mole-
cules and cytokines from endothelial and vascular smooth
muscle cells [19].
This study found significantly lower levels of CCL5
transcription in women on an ABC-containing regimen. Low
baseline CCL5 (RANTES) levels were an independent pre-
dictor of cardiac mortality in male patients followed up
prospectively for 24-months for the occurrence of cardiac
mortality and MI [20]. This followed an earlier study that
associated increased serum levels of IL-8 and reduced levels
of CCL5 with the risk of CHD, after adjustment for known risk
factors [21]. Although there are conflicting reports correlat-
ing elevated levels of CCL5 with adverse cardiac outcomes, it
should be noted that measurement of circulating CCL5 can
be error prone as it can be readily released by activated
platelets during sample collection [22,23]. Nevertheless,
when examining CCL5 transcription, single nucleotide poly-
morphisms that are known to downregulate CCL5 expression
have been linked to cardiac events in a number of studies
[24,25]. CCL5 can bind to both chemokine receptors CCR1
and CCR5, and the loss of either of these receptors is
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Figure 1. Differential expression of cytokine transcript during ART. The Y-axis plots the 2
(DCq) value, with a greater value indicative of
higher gene expression. Differential expression of cytokine transcripts was apparent at ART termination (six-months postpartum) in women
on Trizivir (ABC-based) when compared to those on Kaletra/Combivir (PI-based). Outliers greater than three standard deviations from the
mean are indicated as white data points. ABC, abacavir; ART, antiretroviral therapy; PI, protease inhibitor.
MacLeod IJ et al. Journal of the International AIDS Society 2012, 15:17393
http://www.jiasociety.org/index.php/jias/article/view/17393 | http://dx.doi.org/10.7448/IAS.15.2.17393
4associated with the positive and negative development
of atherosclerosis, respectively, with the absence of CCR5
demonstrating a protective effect by reducing atherosclerotic
plaque formation [26]. However, a well-defined consequence
of reduced CCL5 expression is the coupled upregulation of
CCR5 [20,24]. This feedback mechanism may lead to adverse
cardiovascular outcomes, as a protective effect for CVD, CAD
and MI has been associated with lower levels of CCR5.
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Figure 2. Differential expression of cytokine transcript after ART cessation. The Y-axis plots the 2
(DCq) value, with a greater value
indicative of higher gene expression. There was no difference cytokine gene transcription at 6-months after ART termination (12-months
postpartum) in women on Trizivir (ABC-based) when compared to those on Kaletra/Combivir (PI-based). Outliers greater than three standard
deviations from the mean are indicated as white data points. ABC, abacavir; ART, antiretroviral therapy; PI, protease inhibitor.
Table 2a. Comparison of differentially expressed cytokine transcripts between treatment arms at six and twelve months
ABC-based treatment arm PI-based treatment arm
Mean 95% CI Mean 95% CI Fold change (SD) p
Six months
CCL2 0.003 0.001 to 0.004 0.002 0.001 to 0.003 1.46 (90.53) .366
CCL5 0.325 0.226 to 0.423 0.543 0.401 to 0.684 1.67 (90.33) .035
CCR7 0.056 0.038 to 0.074 0.084 0.050 to 0.118 1.50 (90.38) .304
CD40 0.459 0.302 to 0.616 0.349 0.234 to 0.464 1.32 (90.31) .342
CD40LG 0.060 0.043 to 0.077 0.033 0.024 to 0.042 1.82 (90.35) .027
CXCL1 0.009 0.006 to 0.012 0.007 0.004 to 0.009 1.36 (90.31) .263
CXCL5 0.049 0.033 to 0.064 0.051 0.034 to 0.068 1.05 (90.23) .829
IFNG 10.68 5.16 to 16.20 8.81 4.52 to 13.09 1.21 (90.42) .639
IL8 0.018 0.010 to 0.026 0.006 0.004 to 0.008 3.16 (90.87) .020
LTA 0.335 0.222 to 0.448 0.119 0.080 to 0.158 2.82 (90.65) .008
NFKB1 0.003 0.002 to 0.004 0.004 0.003 to 0.005 1.33 (90.24) .266
TOLLIP 0.067 0.029 to 0.104 0.028 0.014 to 0.043 2.34 (90.86) .140
Twelve months
CCL5 24.32 13.72 to 34.92 12.33 7.80 to 16.87 1.97 (90.54) .198
CD40LG 0.150 0.105 to 0.196 0.171 0.113 to 0.230 1.14 (90.25) .559
CXCL1 0.021 0.014 to 0.029 0.030 0.017 to 0.043 1.40 (90.38) .610
IL8 0.030 0.017 to 0.042 0.039 0.020 to 0.058 1.31 (90.40) .664
LTA 0.092 0.048 to 0.136 0.115 0.066 to 0.165 1.25 (90.39) .601
ABC, abacavir; LTA, lymphotoxin alpha; PI, protease inhibitor.
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5IL-6 is a classical marker of systemic inflammation, yet our
preliminary data showed that approximately 50% of samples
in both arms had levels of IL-6 transcription that were below
the limit of detection. This cytokine was subsequently
excluded from the expanded analysis, as it would have
resulted in data from only 15 samples from each arm.
Furthermore, excluding those that had undetectable IL-6
would have introduced unwanted bias into the data analysis.
There are several limitations to the work outlined here.
This sub-group analysis was matched by CD4 count and viral
load in an attempt to ensure the groups are alike but there
may be unknown biases introduced that would be mitigated
if we were able to use all randomized samples. All of the
women in this study were breastfeeding at the six-month
interval and previous data demonstrate that breastfeeding
raises inflammatory cytokines, although it should increase
cytokines equally in both [27]. However, it may under-
estimate the change between cytokine expression between
the 6- and 12-month period. The period of virologic
suppression was relatively short, and it is unknown if both
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Figure 3. Differential expression of cytokine transcript between 6- and 12-months in individual treatment arms. The Y-axis plots the
2
(DCq) value, with a greater value indicative of higher gene expression. Differential expression of cytokine transcripts was apparent at
6-months after ART termination (12-months postpartum) when compared to ART termination (6-months postpartum) in women in both
treatment arms. Outliers greater than three standard deviations from the mean are indicated as white data points. ART, antiretroviral
therapy.
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6groups would have viral suppression in all reservoirs equally,
and this may contribute to differences between the groups.
While the lopinavir/ritonavir group may have side effects
such as insulin resistance and lipid abnormalities contributing
to increased inflammation, they would more likely bias
towards the null and fail to demonstrate differences in
inflammation rather than the results observed here.
Our data demonstrate the presence of an intracellular
inflammatory response in those treated with ABC-based
antiretrovirals. All of the differentially expressed genes
identified in this study are under the transcriptional control
of NF-kB, a well-established mediator of inflammation, and
these data suggest its possible involvement in mediating
inflammation during ABC-containing ART [2832]. This
correlates with our recently presented findings that Toll-like
receptors may recognize ABC and stimulate an inflammatory
response in vitro [33]. However, the interplay between
multiple signalling pathways makes it difficult to isolate the
transcriptional changes that are possibly attributable to ABC.
It is possible that these differences in cytokine expression are
a reflection of a greater reduction in systemic inflammation
in those treated with a PI-based regiment, but we consider
this to be unlikely as women in both arms attained full
virologic suppression after nine months of ART. Our study
was not designed to evaluate clinical cardiovascular events,
and it is important to note that few cardiovascular events
(and no MIs) occurred in either study arm in this group of
young women with higher CD4 cell counts receiving PMTCT.
In conclusion, our data suggest that ABC may directly
stimulate the expression of proinflammatory cytokines or it
may produce a secondary immunomodulatory effect of
upregulated mediators such as CD40L. There is a need to
expand the scope of research on ABC beyond the traditional
biomarkers of systemic inflammation to understand cellular
messaging and, ultimately, the mechanism of inflammation.
While the pathways involved in mediating inflammation will
need to be the subject of future investigation, it appears that
ABC-containing ART regimens have the capacity to upregu-
late intracellular inflammatory processes.
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